Covered recipient · General Payments record
MANSI RAMESH SHAH
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$101,009.92
108 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,890.72 | 26 |
| Consulting Fee | $23,917.50 | 10 |
| Travel and Lodging | $12,248.78 | 43 |
| Food and Beverage | $1,909.67 | 28 |
| Education | $43.25 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $68,893.29 | 77 |
| Regeneron Healthcare Solutions, Inc. | $10,017.71 | 5 |
| Regeneron Pharmaceuticals, Inc. | $6,015.33 | 10 |
| E.R. Squibb & Sons, L.L.C. | $5,749.79 | 4 |
| PFIZER INC. | $5,560.82 | 4 |
| Janssen Global Services, LLC | $2,420.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,375.00 | 1 |
| Celgene Corporation | $733.60 | 3 |
| Incyte Corporation | $129.75 | 1 |
| GENZYME CORPORATION | $71.38 | 1 |
| AstraZeneca Pharmaceuticals LP | $43.25 | 1 |
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANSI RAMESH SHAH
NPI 1548689763 · CMS profile ID 5701907
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
NEW BRUNSWICK, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MANSI RAMESH SHAH, NPI 1548689763, CMS profile ID 5701907, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548689763?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
108 matching records · $101,009.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–108 of 108.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $3,607.50 | 02/26/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175203507 | CMS |
| Janssen Biotech, Inc. | $113.96 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175203347 | CMS |
| GENZYME CORPORATION | $71.38 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233243697 | CMS |
| Janssen Biotech, Inc. | $3,575.00 | 01/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175203318 | CMS |
| Janssen Biotech, Inc. | $121.85 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175203712 | CMS |
| Janssen Scientific Affairs, LLC | $1,375.00 | 01/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174179947 | CMS |
| Janssen Biotech, Inc. | $26.53 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175202041 | CMS |
| Janssen Biotech, Inc. | $3,575.00 | 01/03/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175202864 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $8,835.52 | 23 |
| PY2025 | Principal investigator | $841,205.23 | 185 |
| PY2024 | Recipient | $827.34 | 4 |
| PY2024 | Principal investigator | $238,289.40 | 43 |
| PY2023 | Recipient | $4,488.54 | 22 |
| PY2023 | Principal investigator | $232,853.43 | 26 |
| PY2022 | Recipient | $847.25 | 1 |
| PY2022 | Principal investigator | $253,965.39 | 14 |
| PY2021 | Principal investigator | $33,932.60 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
208 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $10,623.28 | 12/29/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175339853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,018.60 | 12/29/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175340310 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,422.88 | 12/29/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,608.70 | 12/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184280204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,103.40 | 12/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184280206 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,218.25 | 12/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184280208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,872.20 | 12/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184280210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,705.35 | 12/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184280212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 12/22/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340036 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,267.92 | 12/18/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175340223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,797.67 | 12/18/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175340276 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,035.46 | 12/15/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175339989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,770.10 | 12/15/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340303 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,309.92 | 12/15/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340524 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,259.44 | 12/07/2025 | Covered Recipient Physician | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122439 |
| Principal investigator 1 | ABBVIE INC. | $18,498.10 | 12/04/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202528848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,763.55 | 11/27/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184265903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,711.30 | 11/27/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184265905 |
| Principal investigator 1 | ABBVIE INC. | $21,573.50 | 11/20/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202524800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,103.99 | 11/17/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175340006 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,970.00 | 11/17/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340124 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,293.10 | 11/10/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175339860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $391.30 | 11/07/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | No dispute reported | 06/30/2026 | 1175340510 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,826.20 | 11/06/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122435 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $92.16 | 11/06/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.45 | 10/31/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184256697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.45 | 10/31/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184256699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,711.30 | 10/31/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184256701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,472.85 | 10/31/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184256703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,702.70 | 10/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184255699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,987.72 | 10/27/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175339881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,648.62 | 10/20/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175340352 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,589.00 | 10/13/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma | No dispute reported | 06/30/2026 | 1175340151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,555.24 | 10/06/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,569.48 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy | No dispute reported | 06/30/2026 | 1175340260 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $390.92 | 10/03/2025 | Covered Recipient Physician | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122429 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $366.06 | 10/03/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122431 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $256.64 | 10/03/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246265 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,719.85 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,859.50 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,711.30 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.45 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.45 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,442.45 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,859.50 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,442.45 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,608.70 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,472.85 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,945.95 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,711.30 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,631.50 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,763.55 | 10/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184246299 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,204.77 | 09/19/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122421 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $263.89 | 09/19/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122423 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $388.71 | 09/19/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122425 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $152.24 | 09/19/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,239.62 | 09/04/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340202 |
| Principal investigator 1 | Janssen Research & Development, LLC | $391.30 | 09/04/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | No dispute reported | 06/30/2026 | 1175340397 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,999.75 | 09/01/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175339955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,948.66 | 08/13/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184226919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,851.00 | 07/31/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175339823 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $74.32 | 07/29/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122417 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $196.82 | 07/29/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,819.98 | 07/28/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175339758 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $310.68 | 07/09/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122409 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $508.09 | 07/09/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122411 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $121.27 | 07/09/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122413 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $46.75 | 07/09/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $391.30 | 07/07/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | No dispute reported | 06/30/2026 | 1175340542 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,109.18 | 06/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175340450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $945.24 | 05/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,360.13 | 05/26/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175339798 |
| Principal investigator 1 | Celgene Corporation | $57,261.46 | 05/23/2025 | Non-covered Recipient Entity Rutgers The State University Of New Jersey Audit And Advisory Services | A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL) | No dispute reported | 06/30/2026 | 1222306719 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $304.53 | 05/15/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122405 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $195.26 | 05/15/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122407 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,963.00 | 05/08/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175340434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,195.76 | 05/02/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175340143 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,204.34 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,710.00 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,204.34 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,710.00 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,204.34 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,204.34 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,204.34 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191199 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,710.00 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,021.20 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,074.50 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,072.50 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 04/30/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184191209 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76,888.30 | 04/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175340030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,038.10 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,550.75 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,081.80 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,309.80 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,550.75 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,308.50 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 04/23/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184188187 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $82.29 | 04/14/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122401 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $88.62 | 04/14/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122403 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $412.60 | 04/10/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122399 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $181.31 | 04/09/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,606.50 | 04/04/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184181666 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,097.34 | 04/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175340325 |
| Principal investigator 1 | Janssen Research & Development, LLC | $877.50 | 03/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | No dispute reported | 06/30/2026 | 1175340427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,317.16 | 03/03/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175340482 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,820.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,769.95 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,085.00 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153682 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,170.75 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,619.15 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153688 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,498.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,674.25 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153696 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,085.00 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,769.95 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,820.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153702 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153704 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,946.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153706 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,161.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153708 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,560.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.20 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153712 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153714 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,279.05 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153716 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153718 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,085.00 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,769.95 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,820.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153724 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153726 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,946.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,161.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153730 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,560.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,038.10 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153734 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153736 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153738 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,081.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,619.15 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153748 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,498.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153750 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153752 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,769.95 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153756 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,085.00 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,619.15 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,498.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.20 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,560.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153770 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,161.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,946.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153774 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,820.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.20 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153780 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,085.00 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153782 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,081.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,619.15 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153792 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153794 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,498.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153796 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153798 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,619.15 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153802 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,674.25 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,170.75 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,170.75 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153808 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,279.05 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,038.10 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,081.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,560.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,036.80 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,498.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.20 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,560.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,946.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,096.65 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,820.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,769.95 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.20 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153846 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,674.25 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,161.60 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,946.55 | 02/12/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184153852 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $111.95 | 02/07/2025 | Covered Recipient Physician | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | No dispute reported | 06/30/2026 | 1184122395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,987.72 | 01/24/2025 | Non-covered Recipient Entity RUTGERS THE STATE UNIVERSITY | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R | No dispute reported | 06/30/2026 | 1175339749 |